Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine

Abstract

Background: There is renewed emphasis on including patients in determining, defining, and prioritizing outcomes for migraine treatment.Objectives: To obtain insights directly from people living with migraine on their priorities for treatment.Methods: A total of 40 qualitative interviews were conducted as part of the Migraine Clinical Outcome Assessment System project, a United States Food and Drug Administration grant-funded program to develop a core set of patient-centered outcome measures for migraine clinical trials. Interviews included a structured exercise in which participants rank-ordered pre-defined lists of potential benefits for acute and preventive migraine therapy. The 40 study participants who reported being diagnosed with migraine by a clinician ranked the benefits and explained their rationale.Results: Study participants consistently ranked either pain relief or absence of pain as their top priority for acute treatment. Relief/absence of other migraine symptoms and improved functioning were also prioritized. For preventive treatment, participants prioritized reductions in migraine frequency, symptom severity, and attack duration. Few differences were found between participants with episodic migraine and those with chronic migraine. However, participants with chronic migraine ranked "increased predictability of attacks" much higher than those with episodic migraine. Participants' rankings were influenced by prior expectations and experiences of migraine treatments, which caused many participants to deprioritize desired benefits as unrealistic.Participants also identified several additional priorities, including limited side-effects and reliable treatment efficacy in both acute and preventive treatments. Conclusion:The results showed the participants prioritized treatment benefits aligned with existing core clinical outcomes used in migraine research, but also valued benefits that are not typically assessed, such as predictability. Participants also How to cite this article: Mangrum R, Gerstein MT, Hall CJ III, et al. Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with

CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine

“…According to the World Health Organization (WHO), migraine ranks seventh among the most disabling diseases in the world and third when considering only female sex. Several studies have been conducted on the prevention and treatment of migraine [2,3] by exploring new goals [4]. Migraine attacks can last for a long period of time, from 4 h to several days, and are often associated with symptoms such as vomiting, nausea, and high sensitivity to light and noise.…”

Neurasites®—A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks

“…Mangrum R et al [ 6 ] pointed out a list of rank-ordered benefits for preventive migraine, such as the level of daily physical and intellectual demands, while A-Hassany L et al [ 7 ] evidence the influence of successful prophylaxis duration and the effects of therapy discontinuation.…”

“…In primary care, an ID Migraine Screener [ 6 , 18 ] can be used as a tool for assessing migraine. It screens for migraine-associated features, which are photophobia, functional impairment and nausea.…”